Amount Raised
$200 Million
Round Type
Series B
BurlingameBiotechnologyInvestors
Description
Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing. The fresh capital will enable Genesis to evolve into a clinical stage company, further invest in its state-of-the-art AI platform, and ambitiously expand its discovery pipeline.
Quick answer
Genesis Therapeutics, Inc. raised $200 Million in a Series B round, dated August 21, 2023. Investors: Andreessen Horowitz (a16z) Bio + Health, Eli Lilly, Genentech, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates and N Ventures. Genesis Therapeutics, Inc. is based in Burlingame, California, United States.
- How much did Genesis Therapeutics, Inc. raise?
- Genesis Therapeutics, Inc. raised $200 Million in a Series B round on August 21, 2023.
- Who invested in Genesis Therapeutics, Inc?
- Andreessen Horowitz (a16z) Bio + Health, Eli Lilly, Genentech, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates and N Ventures are named as investors in this round.
- What does Genesis Therapeutics, Inc. do?
- Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and..
- Where is Genesis Therapeutics, Inc. based and how big is it?
- Genesis Therapeutics, Inc. is based in Burlingame, California, United States.
- Who are the decision-makers at Genesis Therapeutics, Inc?
- Fundz holds 2 contacts at Genesis Therapeutics, Inc., including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Genesis Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Oncodesign Precision Medicine raised an undisclosed amount (Funding Round) on October 5, 2023.
- LyGenesis raised $18M on October 5, 2023.
- Integral Molecular raised $900K (Seed) on October 5, 2023.
- Inovedis raised an undisclosed amount (Series A) on October 5, 2023.
- Experic raised an undisclosed amount (Series B) on October 5, 2023.
- Interius raised $21M on October 5, 2023.
Who to call at Genesis Therapeutics, Inc., and when
A new round usually means Genesis Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Genesis Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Genesis Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Genesis Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Genesis Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGenesis Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.